You are here

ASH 2022

45 days later, BioCryst abandons another program, citing stiff competition

45 days later, BioCryst abandons another program, citing stiff competition

Fierce Biotech

Flag link:

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge

EP Vantage

Nurix Therapeutics

Flag link:

ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options

ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options

Fierce Biotech

Flag link:

ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

Fierce Biotech

Flag link:

ASH 2022 – Orchard gets a Sanfilippo boost

ASH 2022 – Orchard gets a Sanfilippo boost

EP Vantage

Orchard Therapeutics

Sanfillipo Syndrome

Flag link:

ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?

ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?

Fierce Pharma

Bristol Myers Squibb

clinical trials

Multiple Myeloma

Flag link:

J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

BioPharma Dive

Multiple Myeloma

Flag link:

ASH: Eli Lilly pads novel BTK's case amid FDA review. But AbbVie-J&J, BeiGene and AZ need not worry

ASH: Eli Lilly pads novel BTK's case amid FDA review. But AbbVie-J&J, BeiGene and AZ need not worry

Fierce Biotech

Flag link:

Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma

Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma

Endpoints

Hodgkin's lymphoma

Flag link:

ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets

ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets

Fierce Biotech

Multiple Myeloma

Bristol Myers Squibb

Flag link:

ASH: Roche records phase 3 rare disease win ahead of Soliris showdown

ASH: Roche records phase 3 rare disease win ahead of Soliris showdown

Fierce Biotech

Flag link:

GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

Fierce Biotech

Sierra Oncology

Flag link:

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle

Fierce Pharma

Flag link:

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

Fierce Pharma

Bristol Myers Squibb

B-cell lymphoma

Flag link:

ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track

ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track

Fierce Pharma

sickle cell disease

Flag link:

ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease

ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease

Fierce Pharma

Flag link:

Setting the Stage for ASH 2022

Setting the Stage for ASH 2022

BioSpace

Vega Therapeutics

Flag link:

ASH preview – waiting for Editas

ASH preview – waiting for Editas

EP Vantage

sickle cell disease

Sangamo BioSciences

Editas Medicine

Vertex Pharmaceuticals

Flag link:

Ash 2022 preview – Affimed and Aptose score

Ash 2022 preview – Affimed and Aptose score

EP Vantage

Aptose Biosciences

Flag link:

Ash 2022 preview – a new multiple myeloma mechanism makes a splash

Ash 2022 preview – a new multiple myeloma mechanism makes a splash

EP Vantage

mutliple myeloma

Flag link: